CROWN — Lorlatinib Versus Crizotinib in First-Line Treatment of Advanced ALK-Positive NSCLC

Phase 3 · 2020 · Non-Small Cell Lung Cancer

Design

Randomized open-label lorlatinib vs crizotinib in treatment-naive ALK-positive disease.

Population

Untreated advanced ALK-positive NSCLC.

Primary Endpoint

progression-free survival (PFS)

Key Result

5-yr PFS 60% vs 8% (HR 0.19); intracranial progression HR 0.06 — unprecedented durability.

Guideline Impact

NCCN category 1 preferred first-line lorlatinib for ALK-positive advanced NSCLC